ClinicalTrials.gov
ClinicalTrials.gov Menu

Levonorgestrel Intrauterine System For Emergency Contraception (LIFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01539720
Recruitment Status : Recruiting
First Posted : February 27, 2012
Last Update Posted : January 30, 2018
Sponsor:
Collaborators:
William and Flora Hewlett Foundation
University of Colorado, Denver
Planned Parenthood Federation of America
University of Rochester
Information provided by (Responsible Party):
Washington University School of Medicine

February 21, 2012
February 27, 2012
January 30, 2018
December 2012
December 2019   (Final data collection date for primary outcome measure)
Pregnancy [ Time Frame: 6 weeks ]
The primary outcome of this study is unintended pregnancy following emergency contraception
Same as current
Complete list of historical versions of study NCT01539720 on ClinicalTrials.gov Archive Site
  • LARC use at 6 and 12 months [ Time Frame: 12 months ]
    Long acting reversible contraception (LARC) use at 6 months following method allocation will be evaluated.
  • Continuation and satisfaction among participants in the LNG-IUS arm [ Time Frame: 12 months ]
    Continuation and satisfaction among participants in the LNG-IUS arm
  • LARC use at 6 months [ Time Frame: 6 months ]
    Long acting reversible contraception (LARC) use at 6 months following method allocation will be evaluated.
  • Continuation and satisfaction among participants in the LNG-IUS arm [ Time Frame: 6 months ]
    Continuation and satisfaction among participants in the LNG-IUS arm
Not Provided
Not Provided
 
Levonorgestrel Intrauterine System For Emergency Contraception
Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial

The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse.

While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.

Unintended pregnancy rates in the United States are among the highest of developed nations. These high rates can largely be attributed to incorrect or under contraception of women. One focus of decreasing unintended pregnancy and abortion rates has centered on expanding access to and use of long acting reversible contraceptive (LARC) methods which include intrauterine devices (IUDs) and subdermal implants. Emergency contraception, or post-coital contraception, offers significant reductions in the chance of pregnancy following an act of unprotected or under-protected vaginal intercourse. The most common methods of emergency contraception used in the United States are the oral levonorgestrel regimen and oral ulipristal acetate (Ella) regimen which reduce pregnancy risk by up to 89%. More effective, but rarely used, is the Cu T-380 intrauterine device (Copper IUD). The IUD has the added benefit of providing extended contraceptive use beyond the single episode of unprotected intercourse. The Cu-T380 has been associated with heavier and more crampy menses however, likely dissuading women from use. Among all IUD users, the levonorgestrel intrauterine system (LNG-IUS) has gained popularity over the Cu-T380, perhaps because it offers the potential to improve menstrual related symptoms. There is no data however on the efficacy of the LNG-IUS as a form of emergency contraception. The purpose of this study is to evaluate the efficacy of the LNG-IUS as a method of emergency contraception. Participants will be randomized to receive either the most common method, oral emergency contraception, or the LNG-IUS. Participants will then be evaluated 5-6 weeks following method allocation for pregnancy. Lastly, participants will be asked to complete a telephone surveys at 6 and 12 months following method allocation assessing their use of a consistent contraceptive method, their satisfaction with their contraceptive method, any use of emergency contraception since their enrollment in the study, and lastly any unintended pregnancies experienced since enrollment in the study. If we could show that the LNG-IUS is as effective as the most commonly prescribed method of emergency contraception, we would be introducing another opportunity for LARC initiation and subsequently impacting unintended pregnancy and abortion rates.
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Pregnancy, Unplanned
  • Pregnancy; Accident
  • Drug: Ulipristal acetate
    30 mg tablet
    Other Name: Ella
  • Device: levonorgestrel IUS
    Levonorgestrel IUS, 52mg placed intrauterine
    Other Names:
    • Mirena IUD
    • Liletta
  • Experimental: Levonorgestrel Intrauterine System
    Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
    Intervention: Device: levonorgestrel IUS
  • Active Comparator: Ulipristal acetate
    Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
    Intervention: Drug: Ulipristal acetate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
532
Same as current
December 2019
December 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women age 14-45
  • Under-protected intercourse within the last five days (120 hours)
  • Willingness to accept either intervention: intrauterine contraception or oral emergency contraception (EC)
  • Ability and willingness to follow-up for in clinic urine pregnancy test (UPT)
  • Ability and willingness to be contacted by phone for 6 and 12 month follow-up

Exclusion Criteria:

  • Positive pregnancy test
  • Non-English speaking
  • Contraindication to intrauterine contraception or oral EC
  • Inability or unwillingness to comply with follow-up
Sexes Eligible for Study: Female
14 Years to 45 Years   (Child, Adult)
Yes
Contact: Colleen P McNicholas, DO 314-747-1425 mcnicholasc@wustl.edu
Contact: Loire Biggs, BA 314-747-1425 loirebiggs@wustl.edu
United States
 
 
NCT01539720
201201007
Yes
Not Provided
Not Provided
Washington University School of Medicine
Washington University School of Medicine
  • William and Flora Hewlett Foundation
  • University of Colorado, Denver
  • Planned Parenthood Federation of America
  • University of Rochester
Principal Investigator: Colleen P McNicholas, DO Washington University School of Medicine
Washington University School of Medicine
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP